Since the formulation of the alternative NMDA theory of schizophrenia, the goal has always been to develop novel, well tolerated and effective treatments. The past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics. Future directions include continued phase III trials and further assessments of the role of sensory processing and individual biomarkers. Although evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.
